Log in

Relevant bibliographies by topics / Metastatic carcinoma / Books

Books on the topic 'Metastatic carcinoma'

To see the other types of publications on this topic, follow the link: Metastatic carcinoma.

Author: Grafiati

Published: 4 June 2021

Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 26 books for your research on the topic 'Metastatic carcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Warner, Ellen. Phase I - II study of vinblastine and oral cyclosporin a in metastatic renal cell carcinoma. Ottawa: National Library of Canada, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

International, Symposium on Cellular Oncology (2nd 1985 Palm Springs Calif ). Occult nodal metastasis in solid carcinomata. New York: Praeger, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Oral cancer metastasis. New York: Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hoogewoud, H. M. Hepatocellular carcinoma and liver metastases: Diagnosis and treatment. Berlin: Springer-Verlag, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

McElligott, Anthony M. The role of matrix metalloproteinases and their inhibitors, the tissue inhibitors of metalloproteinases, in renal cell carcinoma cell invasion and metastasis. [S.l: The Author], 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Surgical Treatment of Metastatic Renal Cell Carcinoma. Derman Tıbbi Yayıncılık, 2015. http://dx.doi.org/10.4328/derman.9786055121242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

A, Stein Cy, and National Cancer Institute (U.S.). Office of Cancer Communications, eds. Suramin, an active agent in metastatic adrenocortical carcinoma. [Bethesda, Md.?]: National Cancer Institute, Office of Cancer Communications, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Huang, William C., and Ezequiel Becher. Advanced and Metastatic Renal Cell Carcinoma an Issue of Urologic Clinics. Elsevier, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text

Abstract:

Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.

APA, Harvard, Vancouver, ISO, and other styles

10

Massey, Veta Hamblen. RELATIONSHIP BETWEEN POWERLESSNESS, HARDINESS, DIAGNOSIS, AND HOPELESSNESS IN PERSONS HOSPITALIZED FOR CHOLECYSTECTOMY OR METASTATIC CARCINOMA. 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Mano, Roy, and Ofer Yossepowitch. Adenocarcinoma of the bladder. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0081.

Full text

Abstract:

Adenocarcinoma of the bladder accounts for 0.5–2 of bladder tumours. Risk factors include bladder exstrophy, bladder augmentation, schistosomiasis, and endometriosis. Bladder adenocarcinoma is classified as primary, arising from the bladder or urachal remnant, and secondary (metastatic). Most patients present with haematuria and irritative voiding symptoms. On imaging, a typical lesion is commonly located at the bladder dome. Compared to urothelial carcinoma (UC), most adenocarcinomas are diagnosed at high grade and advanced stage. Surgical treatment of localized disease entails partial cystectomy for urachal tumours and radical cystectomy for non-urachal or large urachal adenocarcinoma. The optimal treatment for metastatic disease has yet to be defined. Overall survival rates are 20–70% at 5 years, similar to those for UC, when adjusted for stage and grade. Secondary adenocarcinomas commonly arise from a genitourinary or gastrointestinal origin. Differentiation from primary tumours may be complex. Treatment depends on the prognosis of the primary cancer.

APA, Harvard, Vancouver, ISO, and other styles

12

1952-, Wick Mark R., ed. Metastatic carcinomas of unknown origin. New York: DEMOS, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Keshav, Satish, and Palak Trivedi. Liver cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0218.

Full text

Abstract:

Primary hepatocellular carcinoma (HCC) arises from hepatocytes and is one of the commonest solid-organ malignancies in the world, particularly in the Far East and in sub-Saharan Africa. Cholangiocarcinoma arises from the biliary epithelium. The incidence is rising in the West, and primary sclerosing cholangitis (PSC) is an important risk factor (15% lifetime risk). Other forms of liver cancer include metastatic cancer, which is much more common in the West than any primary liver cancer, accounting for 90% of liver cancers and for which common primary sites are the colon, the stomach, the breasts, and the lungs; hepatoblastoma, which is an uncommon malignancy in children, originating from immature liver cell precursors; haemangiosarcomas, which are also rare, are malignant tumours arising from the blood vessels in the liver and can be very rapidly growing; and gall bladder cancer, arising from the gall bladder epithelium. Gallstones and PSC are risk factors for gall bladder cancer; in particular, PSC confers a risk >160 times that of the control population. This chapter primarily focuses on HCC.

APA, Harvard, Vancouver, ISO, and other styles

14

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Full text

Abstract:

Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading >7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed where appropriate by surgery if there is a residual mass. Postoperative radiotherapy should be considered for women having more than one node involved with metastatic tumour at surgery. This must be balanced against the increased risk of lymphoedema where both surgery and radiotherapy are delivered to the groins. Chemoradiation using cisplatin or 5-FU/mitomycin C-based schedules has been reported but no randomized comparison with radiotherapy alone has been undertaken; whilst high response rates are seen there is a considerable increase in acute toxicity.

APA, Harvard, Vancouver, ISO, and other styles

15

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text

Abstract:

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.

APA, Harvard, Vancouver, ISO, and other styles

16

Staehler, Gerd, and Luc P. Balant. Contemporary Research on Renal Cell Carcinoma: Basic and Clinical Developments. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

(Editor), C. G. Bollack, and D. Jacqmin (Editor), eds. Basic Research and Treatment of Renal Cell Carcinoma Metastasis: Proceedings of an Eortc Genitourinary Group Meeting, Held in Strasbourg, France, Nove (Renal Cell Carcinoma Metastasis). Wiley-Liss, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Matin, Rubeta, Jane McGregor, and Catherine Harwood. Skin cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0259.

Full text

Abstract:

Skin cancer is very common in the UK, and its incidence is rising rapidly. There are two broad classes of primary skin cancer: non-melanoma and melanoma. Non-melanoma skin cancer is the commonest form (100 000 cases diagnosed annually in the UK), accounting for nine out of ten skin cancers and includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Cutaneous melanoma is less common (10 000 cases diagnosed in the UK annually) but confers a significantly worse prognosis and accounts for 75% of skin cancer related deaths. There are also a number of other, rarer, non-melanoma skin cancers (e.g. appendageal carcinomas, Merkel cell carcinoma, sarcomas, vascular malignancies, and cutaneous lymphomas); however, these account for less than 1% of all skin cancers in the UK and so will not be specifically discussed in this chapter. Cutaneous metastases can occur secondary to any internal cancer or, indeed, to skin cancer (e.g. melanoma). In most cases, cutaneous metastasis occurs after the diagnosis of a primary cancer and usually in late stages of the disease but, in some cases, it may be the first presentation, in which case it should prompt a thorough investigation for the primary malignancy.

APA, Harvard, Vancouver, ISO, and other styles

19

Myers, Jeffrey. Oral Cancer Metastasis. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Seiichiro, Fujimoto, ed. Paraaortic lymph node metastasis in gynecologic malignancies. Sapporo, Japan: Hokkaido University School of Medicine, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

G, Staehler, and Pomer S, eds. Contemporary research on renal cell carcinoma: Basic and clinical developments. Berlin: Springer-Verlag, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

C, Bollack, Jacqmin D, and European Organization for Research on Treatment of Cancer. Genito-Urinary Tract Cancer Cooperative Group., eds. Basic research and treatment of renal cell carcinoma metastasis: Proceedings of an EORTC Genitourinary Group meeting, held in Strasbourg, France, November 4, 1988. New York: Wiley-Liss, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

(Editor), Moloy, and Ph.D Garth Nicolson (Editor), eds. Occult Nodal Metastasis in Solid Carcinomata: Second International Symposium on Cellular Oncology (Cancer Research Monographs). Praeger Publishers, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

N, Chatzigeorgiou Konstantinos, and Bontis John N, eds. Peritoneal carcinomatosis from ovarian cancer. New York: Nova Science Publishers, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Prati, Raquel, and Olga Olevsky. Breast Cancer Staging and Treatment. Edited by Christoph I. Lee, Constance D. Lehman, and Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0012.

Full text

Abstract:

Breast carcinomas are a heterogeneous group of diseases that can be further characterized based on their histology, biomarkers, and molecular profiles. These characteristics, gathered during disease staging, provide crucial information with regard to treatment decisions. Staging has evolved from informing the operability of breast tumors to providing prognostic information, and consequently helping establish local and systemic treatment guidelines. This chapter provides a succinct overview of breast cancer staging and treatment. Topics covered include the histological classification of breast cancers, as well as classification by tumor size and location, lymph node involvement, and metastatic involvement. The topic of molecular assays for prognostic information is reviewed. Finally, current treatment paradigms, including surgery, radiation, and chemotherapy regimens for different types of breast cancer, are discussed.

APA, Harvard, Vancouver, ISO, and other styles

26

Prasad, Raj K., and Imeshi Wijetunga. Hepatobiliary surgery (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198749813.003.0002.

Full text

Abstract:

This chapter discusses common elective and emergency presentations to hepatobiliary surgery. Gallstone disease, being the commonest hepatobiliary condition encountered by general surgical trainees, is discussed in detail. A separate section on acute ascending cholangitis is included with a brief description of the steps involved in laparoscopic cholecystectomy. Acute pancreatitis is discussed in Pancreatic Surgery Chapter 3. An overview of the assessment and management of post-cholecystectomy complications, such as bile duct injury and vascular injuries, is provided with illustrations. Management of common malignant conditions of the liver, such as colorectal liver metastasis, hepatocellular carcinoma, and cholangiocarcinoma, is included with detailed discussion of pre-operative imaging. Liver resection surgery and liver transplant surgery, as well as non-surgical management, are discussed. Details of post-operative management of hepatobiliary patients are aimed at the junior surgical trainee working in a tertiary hepatobiliary unit to aid day-to-day management of post-operative patients on the wards, as well as subsequent follow-up.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!